KRISHZYME™ Hyaluronidase Enzymatic Assay Kit Reference: KBBA05 Enzymatic Assay for Quantification of Hyaluronidase activity in cell culture supernatant and pharmaceutical preparations Hyaluronidase is a family of enzymes that degrade hyaluronic acid by catalyzing the hydrolysis of hyaluronan, a constituent of the interstitial barrier. Hyaluronidase lowers the viscosity of hyaluronan, thereby increasing tissue permeability. It is, therefore, used in medicine in conjunction with other drugs to speed their dispersion and delivery. About the kit: Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity, Recovery rates are between 85 - 115%, Ready to use with a standard protocol with break-apart pre-coated wells, Validated as per US FDA guidelines for Bioassays, Optimized for matrix effects to ensure higher sensitivity, Shelf life: 1 year. The KRISHZYME™ Hyaluronidase Assay kit uses a two-step turbidimetric reaction to measure hyaluronidase activity by the amount of hyaluronic acid that is hydrolyzed. A stop reagent halts the enzymatic reaction and forms turbidity with any residual hyaluronic acid in the well. The decrease in turbidity at 600 nm is directly proportional to hyaluronidase activity in the sample.
KRISHZYME™ Prekallikrein Activator Assay Kit Reference: KBBA30EP KRISHZYME Plasma Kallikrein Activitor Assay Kit utilizes the ability of active plasma kallikrein to cleave a synthetic pNA-based peptide substrate to release pNA, which can be easily quantified using a microplate reader. The kit is easy-to-use and can detect PK activity of purified plasma kallikrein and plasma samples according to the procedure recommended by the European Pharmacopoeia.
KRIBIOLISA™ Human IgG4 Reference: KBI1007 Immunoassay for the quantification of Human IgG in cell culture and biological samples. About the kit: Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity, Recovery rates are between 85 - 115%, Ready to use with a standard protocol with break-apart pre-coated wells, Validated as per US FDA guidelines for Bioassays, Optimized for matrix effects to ensure higher sensitivity, Shelf life: 1 year
KRIBIOLISA™ E.coli Host Cell DNA Kit Reference: KBBR01 For the production of biotechnological products, expression of therapeutic proteins in E.coli cells is commonly used. Due to which there is a possibility of DNA contamination from the host cells in the products which are manufactured. However, the limit of DNA contamination from the cell lines has been set by regulatory agencies According to WHO the limit of DNA contamination should not exceed 10 ng/dose in the products manufactured. One of the most common method which is widely used for detection of host cell DNA contamination by biopharmaceutical manufacturers is the PicoGreenTM Dye based assay. The research and development department at Krishgen Biosystems has designed a kit to detect and quantify host cell DNA in the products manufactured by recombinant expression in E.coli cell lines based on PicoGreenTM Dye assay. About the kit: Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity, Recovery rates are between 85 - 115%, Ready to use with a standard protocol with break-apart pre-coated wells, Validated as per US FDA guidelines for Bioassays, Optimized for matrix effects to ensure higher sensitivity, Shelf life: 1 year. The Krishgen E.coli Host Cell DNA Kit is based on the DNA dye binding assay which utilizes PicoGreenTM dye. The DNA samples and the standards are reacted with PicoGreenTM dye, which is a DNA intercalator that binds strongly to the double stranded DNA. Upon binding to DNA, PicoGreenTM dye fluoresces with an excitation of 485 nm and emission of 525 nm. The intensity of the fluorescent signal is proportional to the quantity of DNA in the standard or the samples.
KRIBIOLISA™ CHO Host Cell DNA Kit Reference: KBBR02 Immunoassay for the measurement of HEK Host Cell Proteins. For the production of biotechnological products, expression of therapeutic proteins in CHO cells is commonly used. Due to which there is a possibility of DNA contamination from the host cells in the products which are manufactured. However, the limit of DNA contamination from the cell lines has been set by regulatory agencies According to WHO the limit of DNA contamination should not exceed 10ng/dose in the products manufactured. One of the most common method which is widely used for detection of host cell DNA contamination by biopharmaceutical manufacturers is the PicoGreenTM Dye based assay. The research and development department at Krishgen Biosystems has designed a kit to detect and quantify host cell DNA in the products manufactured by recombinant expression in CHO cell lines based on PicoGreenTM Dye assay. About the kit: Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity, Recovery rates are between 85 - 115%, Ready to use with a standard protocol with break-apart pre-coated wells, Validated as per US FDA guidelines for Bioassays, Optimized for matrix effects to ensure higher sensitivity, Shelf life: 1 year. The Krishgen CHO Host Cell DNA Kit is based on the DNA dye binding assay which utilizes PicoGreenTM dye. The DNA samples and the standards are reacted with PicoGreenTM dye, which is a DNA interculator that binds strongly to the double stranded DNA. Upon binding to DNA, PicoGreenTM dye fluoresces with an excitation of 485 nm and emission of 525 nm. The intensity of the fluorescent signal is proportional to the quantity of DNA in the standard or the samples.
KRIBIOLISA™ Insect Cell Host Cell DNA Kit Reference: KBBR03 For the production of biotechnological products, expression of therapeutic proteins in insect cells is commonly used. Due to which there is a possibility of DNA contamination from the host cells in the products which are manufactured. However, the limit of DNA contamination from the cell lines has been set by regulatory agencies According to WHO the limit of DNA contamination should not exceed 10 ng/dose in the products manufactured. One of the most common method which is widely used for detection of host cell DNA contamination by biopharmaceutical manufacturers is the PicoGreenTM Dye based assay. The research and development department at Krishgen Biosystems has designed a kit to detect and quantify host cell DNA in the products manufactured by recombinant expression in insect cell lines based on PicoGreenTM Dye assay. About the kit: Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity, Recovery rates are between 85 - 115%, Ready to use with a standard protocol with break-apart pre-coated wells, Validated as per US FDA guidelines for Bioassays, Optimized for matrix effects to ensure higher sensitivity, Shelf life: 1 year. The Krishgen Insect Cell Host Cell DNA Kit is based on the DNA dye binding assay which utilizes PicoGreenTM dye. The DNA samples and the standards are reacted with PicoGreenTM dye, which is a DNA intercalator that binds strongly to the double stranded DNA. Upon binding to DNA, PicoGreenTM dye fluoresces with an excitation of 485 nm and emission of 525 nm. The intensity of the fluorescent signal is proportional to the quantity of DNA in the standard or the samples.
KRIBIOLISA™ Protein L Ligand Detection Kit Reference: KBBP50 Enzyme Immunoassay for the Quantitative determination of Protein L Ligand Detection from medium containing immunoglobulin (Ig) or Ig-fragments
IDO1 (human) Enzyme+Inhibitor Set Reference: AG-44B-0006 IDO1 is a heme-containing enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, that plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. The IDO1 (human) Enzyme+Inhibitor Set contains the active enzyme IDO1 (human) (rec.) (His) (AG-40B-0161), compound MMG-0358 (AG-CR1-3630), a very potent and specific inhibitor of IDO1, and protocols that can be used for IDO1 enzyme activity and IDO1 inhibition experiments. Both components can be used in vitro: • For cell culture to study the effect of hIDO1 in a cellular system.• For screening assay to search for new inhibitors of hIDO1.
RELM-beta (human) Matched Pair Detection Set Reference: AG-46A-0001 RELM-beta is a 19kDa disulfide-linked homodimeric protein expressed in the epithelium of the colon and small bowel. RELM-beta has been suggested to play a regulatory role during inflammation and may also act to establish links among adipose tissue, the intestine and the liver. Interestingly, the molecular structure of RELM-beta is highly homologous to that of the adipose-derived cytokine resistin. The specific and sensitive RELM-beta Matched Pair Detection Set might detect RELM-beta in serum of gut-inflamed patients (e.g. inflammatory bowel diseases, Crohn disease and ulcerative colitis). Natural levels of RELM-beta were seen in stool, but were not detectable in the serum or other cell culture models of healthy human patients. Further testing are ongoing.
BAFF, Soluble (human) Matched Pair Detection Set Reference: AG-46B-0001 BAFF (B cell-activating factor; BLyS; B lymphocyte stimulator; TNFSF13B; TALL-1; CD257), belonging to the TNF family, is a master regulator of peripheral B cell survival, and together with IL-6, promotes Ig class-switching and plasma cell differentiation. BAFF co-stimulates activated T cells. Increased levels of soluble BAFF have been detected in the serum of patients with various autoimmune diseases, such as Sjögren’s syndrome, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (SLE). Furthermore, BAFF is found in inflammatory sites in which there is lymphoid neogenesis. BAFF levels are elevated in patients with multiple myeloma and B cell chronic lymphoid leukemia (B-CCL).